Current through the 2024 Fourth Special Session
Section 64-13-25.1 - Medication assisted treatment plan(1) As used in this section, "medication assisted treatment plan" means a prescription plan to use a medication, such as buprenorphine, methadone, or naltrexone, to treat substance use withdrawal symptoms or an opioid use disorder.(2) In collaboration with the Department of Health and Human Services the department may cooperate with medical personnel to continue a medication assisted treatment plan for an inmate who had an active medication assisted treatment plan within the last six months before being committed to the custody of the department.(3) A medication used for a medication assisted treatment plan under Subsection (2): (a) shall be an oral, short-acting medication unless the chief administrative officer or other medical personnel who is familiar with the inmate's medication assisted treatment plan determines that a long-acting, non-oral medication will provide a greater benefit to the individual receiving treatment;(b) may be administered to an inmate under the direction of the chief administrative officer of the correctional facility;(c) may, as funding permits, be paid for by the department or the Department of Health and Human Services; and(d) may be left or stored at a correctional facility at the discretion of the chief administrative officer of the correctional facility.(4) Before November 30 each year, the Department of Health and Human Services shall provide a report to the Health and Human Services Interim Committee that details, for each category, the number of individuals in the custody of the department who, in the preceding 12 months:(a) had an active medication assisted treatment plan within the six months preceding commitment to the custody of the department;(b) continued a medication assisted treatment plan following commitment to the custody of the department; and(c) discontinued a medication assisted treatment plan prior to, at the time of, or after commitment to the custody of the department and, as available, the type of medication discontinued and the reason for the discontinuation.Added by Chapter 266, 2024 General Session ,§ 3, eff. 5/1/2024.